1. Stevens J. Storming heaven: LSD and the American dream. New York: Grove Press; 1987.

2. Hoffman AJ, Nichols DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J Med Chem. 1985;28(9):1252–5.

3. Oberlender R, Pfaff RC, Johnson MP, Huang XM, Nichols DE. Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane. J Med Chem. 1992;35(2):203–11.

4. Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol Biochem Behav. 1994;47(3):667–73.

5. Monte AP, Marona-Lewicka D, Kanthasamy A, Sanders-Bush E, Nichols DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J Med Chem. 1995;38(6):958–66.

6. Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). J Med Chem. 2002;45(19):4344–9.

7. Shulgin A, Shulgin A. Tihkal: the continuation. Berkeley: Transform Press; 1997.

8. Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE. Lysergamides revisited. NIDA Res Monogr. 1994;146:52–73.

9. Nichols DE. LSD and its lysergamide cousins. Heffter Rev Psychedelic Res. 2001;2:80–7.

10. Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264–355.

11. Nichols DE. Dark classics in chemical neuroscience: lysergic acid diethylamide (LSD). ACS Chem Neurosci. 2018;9(10):2331–43.

12. Liechti ME. Modern clinical research on LSD. Neuropsychopharmacology. 2017;42(11):2114–27.

13. Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, et al. Return of the lysergamides. Part I: analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). Drug Test Anal. 2016;8(9):891–902.

14. Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, et al. Return of the lysergamides. Part III: analytical characterization of N(6) -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). Drug Test Anal. 2017;9(10):1641–9.

15. Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, et al. Return of the lysergamides. Part II: analytical and behavioural characterization of N(6) -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ). Drug Test Anal. 2017;9(1):38–50.

16. Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, et al. Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology. 2018. https://doi.org/10.1007/s00213-018-5055-9.

17. Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J et al. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Test Anal. 2018;10(2):310–22.

18. EMCDDA. European drug report 2017: trends and developments. Publications of of the European Union 2017.

19. Canezin J, Cailleux A, Turcant A, Le Bouil A, Harry P, Allain P. Determination of LSD and its metabolites in human biological fluids by high-performance liquid chromatography with electrospray tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 2001;765(1):15–27.

20. Dolder PC, Liechti ME, Rentsch KM. Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases. Anal Bioanal Chem. 2015;407(6):1577–84.

21. Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME. Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans. Int J Neuropsychopharmacol. 2015;19(1).

22. Diao X, Huestis MA. Approaches, challenges, and advances in metabolism of new synthetic cannabinoids and identification of optimal urinary marker metabolites. Clin Pharmacol Ther. 2017;101(2):239–53.

23. Welter-Luedeke J, Maurer HH. New psychoactive substances: chemistry, pharmacology, metabolism, and detectability of amphetamine derivatives with modified ring systems. Ther Drug Monit. 2016;38(1):4–11.

24. Meyer MR. New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics. Arch Toxicol. 2016;90(10):2421–44.

25. Meyer MR. Toxicokinetics of NPS: update 2017. Handb Exp Pharmacol. 2018. https://doi.org/10.1007/164_2018_102.

26. Mogler L, Wilde M, Huppertz LM, Weinfurtner G, Franz F, Auwarter V. Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples. Drug Test Anal. 2018;10(5):886-91.

27. Watanabe S, Vikingsson S, Roman M, Green H, Kronstrand R, Wohlfarth A. In vitro and in vivo metabolite identification studies for the new synthetic opioids acetylfentanyl, acrylfentanyl, furanylfentanyl, and 4-fluoro-isobutyrylfentanyl. AAPS J. 2017;19(4):1102–22.

28. Welter J, Meyer MR, Wolf EU, Weinmann W, Kavanagh P, Maurer HH. 2-Methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques. Anal Bioanal Chem. 2013;405(10):3125–35.

29. Richter LHJ, Flockerzi V, Maurer HH, Meyer MR. Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV, MDPB, 5-MAPB, and 5-API as examples. J Pharm Biomed Anal. 2017;143:32–42.

30. Chauret N, Gauthier A, Nicoll-Griffith DA. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos. 1998;26(1):1–4.

31. Wagmann L, Meyer MR, Maurer HH. What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett. 2016;258:55–70.

32. Meyer GM, Meyer MR, Wink CS, Zapp J, Maurer HH. Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse. Biochem Pharmacol. 2013;86(10):1497–506.

33. Wagmann L, Brandt SD, Kavanagh PV, Maurer HH, Meyer MR. In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks. Toxicol Lett. 2017;272:84–93.

34. Welter J, Kavanagh P, Meyer MR, Maurer HH. Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques. Anal Bioanal Chem. 2015;407(5):1371–88.

35. Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH. Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening—exemplified for cardiovascular drugs. Anal Chim Acta. 2015;891:221–33.

36. Caspar AT, Westphal F, Meyer MR, Maurer HH. LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques. Anal Bioanal Chem. 2018;410(3):897–912.

37. Wissenbach DK, Meyer MR, Remane D, Philipp AA, Weber AA, Maurer HH. Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept. Anal Bioanal Chem. 2011;400(10):3481–9.

38. Meyer MR, Lindauer C, Welter J, Maurer HH. Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography-linear ion-trap (high-resolution) mass spectrometry. Anal Bioanal Chem. 2014;406(7):1845–54.

39. Maurer HH, Pfleger K, Weber AA. Mass spectral data of drugs, poisons, pesticides, pollutants and their metabolites. Wiley-VCH: Weinheim; 2016.

40. Klette KL, Anderson CJ, Poch GK, Nimrod AC, ElSohly MA. Metabolism of lysergic acid diethylamide (LSD) to 2-oxo-3-hydroxy LSD (O-H-LSD) in human liver microsomes and cryopreserved human hepatocytes. J Anal Toxicol. 2000;24(7):550–6.

41. Poch GK, Klette KL, Hallare DA, Manglicmot MG, Czarny RJ, McWhorter LK, et al. Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD. J Chromatogr B Biomed Sci Appl. 1999;724(1):23–33.

42. Steuer AE, Poetzsch M, Stock L, Eisenbeiss L, Schmid Y, Liechti ME, et al. Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. Drug Test Anal. 2017;9(5):788–97.

43. Dolder PC, Liechti ME, Rentsch KM. Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial. J Clin Lab Anal. 2018;32(2).

44. Favretto D, Frison G, Maietti S, Ferrara SD. LC-ESI-MS/MS on an ion trap for the determination of LSD, iso-LSD, nor-LSD and 2-oxo-3-hydroxy-LSD in blood, urine and vitreous humor. Int J Legal Med. 2007;121(4):259–65.

45. Jang M, Kim J, Han I, Yang W. Simultaneous determination of LSD and 2-oxo-3-hydroxy LSD in hair and urine by LC-MS/MS and its application to forensic cases. J Pharm Biomed Anal. 2015;115:138–43.

46. Johansen SS, Jensen JL. Liquid chromatography-tandem mass spectrometry determination of LSD, ISO-LSD, and the main metabolite 2-oxo-3-hydroxy-LSD in forensic samples and application in a forensic case. J Chromatogr B Anal Technol Biomed Life Sci. 2005;825(1):21–8.

47. Richter LHJ, Maurer HH, Meyer MR. New psychoactive substances: studies on the metabolism of XLR-11, AB-PINACA, FUB-PB-22, 4-methoxy-alpha-PVP, 25-I-NBOMe, and meclonazepam using human liver preparations in comparison to primary human hepatocytes, and human urine. Toxicol Lett. 2017;280:142–50.

48. Niessen WM, Correa RA. Interpretation of MS-MS mass spectra of drugs and pesticides. Hoboken: Wiley; 2016.

49. Wink CS, Meyer GM, Meyer MR, Maurer HH. Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs—contribution of human cytochrome P450 isozymes to their main phase I metabolic steps. Toxicol Lett. 2015;238(3):39–44.

50. Koonrungsesomboon N, Khatsri R, Wongchompoo P, Teekachunhatean S. The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis. Pharmacogenomics J. 2018;18(6):760–8.

51. Nichols DE, Grob CS. Is LSD toxic? Forensic Sci Int. 2018;284:141–5.

52. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14(4):295–314.

53. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol. 2009;157(6):907–21.

54. Crews C. Analysis of ergot alkaloids. Toxins (Basel). 2015;7(6):2024–50.